

# Lu Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2807093/publications.pdf>

Version: 2024-02-01

92  
papers

898  
citations

566801

15  
h-index

642321

23  
g-index

109  
all docs

109  
docs citations

109  
times ranked

1122  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma. <i>Scientific Reports</i> , 2016, 6, 38671.	1.6	67
2	A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. <i>American Journal of Hematology</i> , 2018, 93, 803-809.	2.0	49
3	Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. <i>Blood</i> , 2019, 133, 1720-1728.	0.6	45
4	What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone?. <i>Leukemia</i> , 2019, 33, 1023-1029.	3.3	43
5	Consumption and Sources of Dietary Salt in Family Members in Beijing. <i>Nutrients</i> , 2015, 7, 2719-2730.	1.7	37
6	Effects of whey protein nutritional supplement on muscle function among community-dwelling frail older people: A multicenter study in China. <i>Archives of Gerontology and Geriatrics</i> , 2019, 83, 7-12.	1.4	34
7	Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. <i>Annals of Hematology</i> , 2018, 97, 1641-1647.	0.8	26
8	Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis. <i>American Journal of Hematology</i> , 2022, 97, 203-208.	2.0	25
9	Clinical spectrum and survival analysis of 145 cases of HIV-negative Castleman's disease: renal function is an important prognostic factor. <i>Scientific Reports</i> , 2016, 6, 23831.	1.6	24
10	Prognostic value of serum vascular endothelial growth factor and hematological responses in patients with newly-diagnosed POEMS syndrome. <i>Blood Cancer Journal</i> , 2018, 8, 37.	2.8	22
11	Primary extra-nodal diffuse large B-cell lymphoma: A prognostic analysis of 141 patients. <i>Oncology Letters</i> , 2018, 16, 1602-1614.	0.8	22
12	The anti-malaria drug artesunate inhibits cigarette smoke and ovalbumin concurrent exposure-induced airway inflammation and might reverse glucocorticoid insensitivity. <i>International Immunopharmacology</i> , 2015, 29, 235-245.	1.7	21
13	Next-generation sequencing-based genetic landscape and its clinical implications for Chinese acute myeloid leukemia patients. <i>Cancer Cell International</i> , 2018, 18, 215.	1.8	19
14	Baseline bone marrow ADC value of diffusion-weighted MRI: a potential independent predictor for progression and death in patients with newly diagnosed multiple myeloma. <i>European Radiology</i> , 2021, 31, 1843-1852.	2.3	19
15	Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China. <i>Journal of Infection and Chemotherapy</i> , 2017, 23, 360-367.	0.8	18
16	Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 66-73.	1.4	17
17	A highly heterogeneous mutational pattern in POEMS syndrome. <i>Leukemia</i> , 2021, 35, 1100-1107.	3.3	17
18	Down-regulation of microRNA-30d-5p is associated with gestational diabetes mellitus by targeting RAB8A. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107959.	1.2	16

#	ARTICLE	IF	CITATIONS
19	At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment. <i>Annals of Hematology</i> , 2017, 96, 2089-2094.	0.8	15
20	Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients. <i>Annals of Hematology</i> , 2020, 99, 1735-1740.	0.8	13
21	Bortezomib plus dexamethasone as first-line therapy for patients with POEMS syndrome. <i>Annals of Hematology</i> , 2021, 100, 2755-2761.	0.8	13
22	A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD. <i>Leukemia and Lymphoma</i> , 2022, 63, 618-626.	0.6	13
23	Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels. <i>Annals of Hematology</i> , 2018, 97, 2465-2470.	0.8	12
24	Posttreatment dFLC less than 10%mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib. <i>Leukemia and Lymphoma</i> , 2021, 62, 874-882.	0.6	12
25	Recurrent pulmonary mucormycosis after lobectomy in a non-smoking patient without predisposing risk factors. <i>Brazilian Journal of Infectious Diseases</i> , 2012, 16, 590-593.	0.3	11
26	Clinical characteristics and the long-term outcome of patients with atypical POEMS syndrome variant with undetectable monoclonal gammopathy. <i>Annals of Hematology</i> , 2019, 98, 735-743.	0.8	11
27	A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study. <i>Oncologist</i> , 2020, 25, 963-973.	1.9	11
28	UCD with MCD-like inflammatory state: surgical excision is highly effective. <i>Blood Advances</i> , 2021, 5, 122-128.	2.5	11
29	Treatment and outcomes of POEMS syndrome: changes in the past 20 years. <i>Blood Cancer Journal</i> , 2021, 11, 145.	2.8	11
30	Prevalence and risk factors for depression in newly diagnosed patients with POEMS syndrome. <i>Leukemia and Lymphoma</i> , 2014, 55, 2835-2841.	0.6	10
31	Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) associated with or without lymphoma: Comparison of clinical features and risk factors suggestive of underlying lymphomas. <i>Journal of Clinical Neuroscience</i> , 2019, 66, 156-164.	0.8	10
32	Bortezomib-based chemotherapy can improve renal and tubular functions in patients with light chain-associated Fanconi syndrome. <i>Annals of Hematology</i> , 2019, 98, 1095-1100.	0.8	10
33	Peripheral T cell lymphoma after chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS): a case report. <i>BMC Neurology</i> , 2019, 19, 266.	0.8	9
34	Sjögren's syndrome initially presented as thrombotic thrombocytopenic purpura in a male patient: a case report and literature review. <i>Clinical Rheumatology</i> , 2018, 37, 1421-1426.	1.0	8
35	Clinical presentation and prognostic analysis of Chinese patients with systemic light chain amyloidosis with liver involvement. <i>Leukemia Research</i> , 2019, 86, 106226.	0.4	8
36	Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy: A Single-Center Cohort Study of 227 Patients. <i>Circulation Journal</i> , 2019, 83, 775-782.	0.7	8

#	ARTICLE	IF	CITATIONS
37	Haplotype-based association of two SNPs in miR-423 with unexplained recurrent pregnancy loss in a Chinese Han population. <i>Experimental Cell Research</i> , 2019, 374, 210-220.	1.2	8
38	Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 255-256.	1.4	7
39	Intravenous methotrexate at a dose of 1 g/m <sup>2</sup> incorporated into RCHOP prevented CNS relapse in high-risk DLBCL patients: A prospective, historic controlled study. <i>American Journal of Hematology</i> , 2020, 95, E80-E83.	2.0	7
40	HIV-1 molecular epidemiology and drug resistance-associated mutations among treatment-naïve blood donors in China. <i>Scientific Reports</i> , 2020, 10, 7571.	1.6	7
41	Acute Kidney Injury Caused by TAFRO Syndrome in a Chinese Patient: Efficacy of Long-Term Corticosteroids Combined with Bortezomib and Cyclophosphamide. <i>Kidney and Blood Pressure Research</i> , 2020, 45, 623-630.	0.9	7
42	Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia. <i>Annals of Hematology</i> , 2020, 99, 1141-1143.	0.8	7
43	Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multicentre, prospective, non-interventional study. <i>Age and Ageing</i> , 2022, 51, .	0.7	7
44	Impact of Physicians' Personalities and Behavioral Traits on Treatment-Related Decision-making for Elderly Acute Myeloid Leukemia. <i>Journal of General Internal Medicine</i> , 2021, 36, 3023-3030.	1.3	7
45	Comparative Evaluation and Measure of Accuracy of ELISAs, CLIAs, and ECLIAs for the Detection of HIV Infection among Blood Donors in China. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2020, 2020, 1-9.	0.7	6
46	Identification of potential indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors by an FBG-based 3D QSAR pharmacophore model. <i>Journal of Molecular Graphics and Modelling</i> , 2020, 99, 107628.	1.3	6
47	Home Treatment of Bortezomib: A Preliminary Exploration of a New Treatment Mode in China. <i>Blood</i> , 2019, 134, 2127-2127.	0.6	6
48	Updated Phase 1 Results of C-CAR088, an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 1830-1830.	0.6	6
49	TAFRO Syndrome – A Specific Subtype of Castleman's Disease in China. <i>Chinese Medical Journal</i> , 2018, 131, 1868-1870.	0.9	5
50	Clinical presentation and prognosis of immunoglobulin light-chain amyloidosis with high percentage of bone marrow plasma cells. <i>Leukemia Research</i> , 2019, 81, 19-24.	0.4	5
51	Effects of yoga on exercise capacity in patients with lymphangiomyomatosis: a nonrandomized controlled study. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 72.	1.2	5
52	Identification of novel xanthine oxidase inhibitors via virtual screening with enhanced characterization of molybdopterin binding groups. <i>European Journal of Medicinal Chemistry</i> , 2022, 230, 114101.	2.6	5
53	Clinical Analysis of Unicentric Castleman's Disease with Paraneoplastic Pemphigus and Bronchiolitis Obliterans. <i>Zhongguo Yi Xue Ke Xue Yuan Xue Bao Acta Academiae Medicinae Sinicae</i> , 2017, 39, 492-498.	0.2	5
54	Patients with Fever of Unknown Origin and Splenomegaly: Diagnostic Value of Splenectomy and Preoperative Risk Factors Suggestive of Underlying Lymphomas. <i>Acta Haematologica</i> , 2017, 137, 240-246.	0.7	4

#	ARTICLE	IF	CITATIONS
55	Concomitant cryoglobulinemic vasculitis and cold agglutinin disease successfully treated with bortezomib. <i>Medicine (United States)</i> , 2019, 98, e14201.	0.4	4
56	Amyloidosis secondary to intrapulmonary Castleman disease mimicking pulmonary hyalinizing granuloma-like clinical features. <i>Medicine (United States)</i> , 2019, 98, e15039.	0.4	4
57	Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study. <i>Annals of Hematology</i> , 2020, 99, 2801-2809.	0.8	4
58	HIV-1 gp41 genetic diversity and enfuvirtide resistance-associated mutations among enfuvirtide-naïve patients in southern China. <i>Virus Research</i> , 2021, 292, 198215.	1.1	4
59	Revealing serum lipidomic characteristics and potential lipid biomarkers in patients with POEMS syndrome. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4307-4315.	1.6	4
60	Clinical Features of Patients with Castleman's Disease Complicated Systemic Lupus Erythematosus. <i>Zhongguo Yi Xue Ke Xue Yuan Xue Bao Acta Academiae Medicinae Sinicae</i> , 2016, 38, 543-547.	0.2	4
61	Primary Adrenal Insufficiency Due to Bilateral Adrenal Hematomas in a Patient with Primary Antiphospholipid Syndrome. <i>Chinese Medical Journal</i> , 2017, 130, 2517-2518.	0.9	3
62	Cholangiocarcinoma presenting with acquired thrombotic thrombocytopenic purpura confirmed by positive autoantibodies of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13. <i>Chinese Medical Journal</i> , 2020, 133, 1495-1496.	0.9	3
63	Long-term treatment response to PD-1 blockade therapy in a patient with DLBCL relapsed after anti-CD19 chimeric antigen receptor T cell treatment. <i>Annals of Hematology</i> , 2021, 100, 289-291.	0.8	3
64	Is physical capacity correlated with health-related quality of life in patients with adolescent idiopathic scoliosis?. <i>Annals of Palliative Medicine</i> , 2021, 10, 6220-6227.	0.5	3
65	Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study. <i>Annals of Hematology</i> , 2022, 101, 831-836.	0.8	3
66	Langerhans Histiocytosis Renders a Differential and Complementary Diagnosis for a Sjögren Syndrome Female Presenting with a Hypophyseal Mass, Pulmonary Emphysema and Thyroid Nodules. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 189-191.	0.3	2
67	Well-differentiated systemic mastocytosis with KIT K509I mutation and uterus infiltration in an Asian woman with good response to imatinib. <i>Chinese Medical Journal</i> , 2019, 132, 2002-2003.	0.9	2
68	A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia. <i>Turkish Journal of Haematology</i> , 2021, 38, 87-89.	0.2	2
69	Histogram Analysis Based on Apparent Diffusion Coefficient Maps of Bone Marrow in Multiple Myeloma: An Independent Predictor for High-risk Patients Classified by the Revised International Staging System. <i>Academic Radiology</i> , 2022, 29, e98-e107.	1.3	2
70	The Interim Analysis from a Prospective Single-Center Phase 2 Study of Zanubrutinib Plus R-CHOP in Treat-Naïve Intravascular Large B Cell Lymphoma. <i>Blood</i> , 2021, 138, 3563-3563.	0.6	2
71	Evaluation of ELISA and CLIA for <i>Treponema pallidum</i> specific antibody detection in China: A multicenter study. <i>Journal of Microbiological Methods</i> , 2019, 166, 105742.	0.7	1
72	The role of high serum CXCL13 level in Waldenström macroglobulinemia. <i>Leukemia Research</i> , 2019, 81, 50-55.	0.4	1

#	ARTICLE	IF	CITATIONS
73	Blue Rubber Bleb Nevus Syndrome: A Possible Cause for Growth Retardation and Pubertal Delay. <i>Medical Principles and Practice</i> , 2019, 28, 294-296.	1.1	1
74	Cerebral thrombotic event as a rare complication in a young female patient with idiopathic multicentric castleman disease. <i>Clinical Neurology and Neurosurgery</i> , 2020, 198, 106246.	0.6	1
75	Dynamic hematological changes in patients undergoing distal pancreatectomy with or without splenectomy: a population-based cohort study. <i>BMC Surgery</i> , 2020, 20, 265.	0.6	1
76	A case of idiopathic multicentric Castleman disease presenting with diffuse lung cysts: how to evaluate treatment response?. <i>Annals of Hematology</i> , 2020, 99, 1401-1402.	0.8	1
77	Validation of the composite organ and hematologic response model for prognostic prediction in a Chinese light chain amyloidosis cohort. <i>Leukemia and Lymphoma</i> , 2021, 62, 1892-1896.	0.6	1
78	Extranodal NK/T-Cell Lymphoma Occurring Primarily in the Eyes and with Central Nervous System Relapse. <i>Cancer Management and Research</i> , 2021, Volume 13, 6579-6583.	0.9	1
79	Pathogenesis of Castleman's Disease. <i>Zhongguo Yi Xue Ke Xue Yuan Xue Bao Acta Academiae Medicinae Sinicae</i> , 2016, 38, 118-21.	0.2	1
80	Methotrexate and Cytarabine for Adult Patients with Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study. <i>Blood</i> , 2019, 134, 294-294.	0.6	1
81	Impact of Hematologists' Personality and Behavioral Traits on Medical Decision-Making for Elderly Acute Myeloid Leukemia: A National Study in China. <i>Blood</i> , 2020, 136, 19-19.	0.6	1
82	A Prospective, Multicenter Study of Bortezomib, Cyclophosphamide and Dexamethasone in Relapsed/Refractory Idiopathic Multicentric Castleman's Disease. <i>Blood</i> , 2020, 136, 42-42.	0.6	1
83	A retrospective study of ultrahigh-risk (Mayo 2004 stage IIIb) AL amyloidosis and identification of predictors related to extremely early death. <i>Leukemia and Lymphoma</i> , 2022, 63, 1758-1761.	0.6	1
84	Selection of Biopsy Site for Patients with Systematic Amyloidosis. <i>Zhongguo Yi Xue Ke Xue Yuan Xue Bao Acta Academiae Medicinae Sinicae</i> , 2016, 38, 706-709.	0.2	1
85	Acute promyelocytic leukaemia with promyelocyte count below 20%. <i>British Journal of Haematology</i> , 2016, 173, 11-11.	1.2	0
86	Gastric Cancer or Plasmacytoma in a Seemingly Well-Controlled Multiple Myeloma Patient?. <i>Turkish Journal of Haematology</i> , 2021, 38, 169-170.	0.2	0
87	Survival Comparison of Three Treatment Regimens of POEMS Syndrome: A Single-Center Retrospective Study. <i>Blood</i> , 2018, 132, 3428-3428.	0.6	0
88	Bortezomib-Based Chemotherapy Reduces Early Mortality and Improves Outcomes in Patients with Ultra-High-Risk Light-Chain Amyloidosis. <i>Blood</i> , 2018, 132, 3304-3304.	0.6	0
89	Unusual co-occurrence of cold agglutinin disease in a bladder transitional cell carcinoma patient with unexplained anemia and cold-related symptoms. <i>Chinese Medical Journal</i> , 2021, 134, 608-610.	0.9	0
90	A Highly Heterogeneous Mutational Pattern in POEMS Syndrome. <i>Blood</i> , 2020, 136, 19-19.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Treatment Outcome and Prognostic Factors for Adult Langerhans Cell Histiocytosis. Blood, 2020, 136, 38-38.	0.6	0
92	Unicentric Castleman Disease with High Inflammatory State: Surgical Treatment Is a Potential Cure. Blood, 2020, 136, 14-15.	0.6	0